Olatec Therapeutics LLC

Chemic Laboratories, Inc.

Olatec Industries LLC

Chemsmart, LLC

Mind Medicine, Inc.

Jsb Pharma Development, LLC

Koda Therapeutics, LLC

Gerald S Jones

Joseph St Laurent

Scott A Goodrich

David M Bresse

Stephen E Schneider

George M Shopp

Peter Mack

Jon Schroeder

Robert Barrow

David M Breese

George Maguire

Joseph P St Laurent

Described herein are compounds that act as antimicrobial agents, compositions comprising these compounds, and methods of their use in to treating infections caused by() or killing or inhibiting the growth of

Antimicrobial agents and compositions and uses thereof

A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.

Formulations of psilocin that have enhanced stability

Described herein are methods for making folic acid derivatives, intermediates, pharmaceutical compositions and uses thereof.

Compositions comprising folic acid derivatives, their preparations and methods of use

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a methanesulfonylalkylnitrile compound, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering a methanesulfonylalkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Pharmaceutical composition for treating inflammation and pain

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and &#x3c9;-(methylsulfonyl)alkylamine or &#x3c9;-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering &#x3c9;-(methylsulfonyl)alkylamine or &#x3c9;-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Pharmaceutical composition

The present invention relates to purified compounds of 3-methanesulfonylpropionitrile, in which at least one of the hydrogen, oxygen, sulfur, and nitrogen atoms is substituted with a respective isotope that includes, but not limited toH (deuterium),H (tritium),C,C,N,O,O, andS. The purified compound has at least 90% purity. Preferred compounds are deuterated 3-methanesulfonylpropionitriles.

Deuterated 3-methanesulfonylpropionitrile

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-benzylsulfonylpropionitrile, or its pharmaceutically acceptable salts. The present invention also relates to methods of using the compound for treating inflammation or inflammatory-related disorders and pain.

Pharmaceutical use of 3-benzylsulfonylpropionitrile

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering &#x3c9;-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3-benzylsulfonylpropionitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

4-benzylsulfonyl-2-butenenitrile

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a &#x3c9;-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an &#x3c9;-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile

The present invention relates to processes for preparing for preparing 3-(methylsulfonyl)propionitrile. The processes comprise the steps of first reacting 2-chloroethyl methyl sulfide with sodium cyanide or potassium cyanide in a solvent or a solvent mixture to form 3-(methylthio)propionitrile, and then reacting the isolated 3-(methylthio)propionitrile with acetic anhydride, acetic acid, and hydrogen peroxide to form 3-(methylsulfonyl)propionitrile.

Growing community of inventors

Norwood, MA, United States of America

Gerald S Jones